Novo Nordisk diabetes treatment backed by EU

Novo Nordisk's new diabetes treatment has been cleared for use across the European Union.

Ozempic has been approved as a monotherapy to treat adults with type 2 diabetes if metformin is not considered an appropriate therapy.

The once-weekly analogue of human glucagon-like peptide-1 (GLP-1) will be available in a multi-dose pen form, with the rollout expected to commence in the second half of the year.

Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk, commented: "We are very excited about the approval of Ozempic in the EU, as we believe it has the potential to set a new standard for the treatment of type 2 diabetes."

He described type 2 diabetes as a complex disease, but added the strong clinical profile of Ozempic provides a "much-needed treatment option for people looking for efficacious solutions to manage their disease".

Ozempic has already been approved by regulators in the US in recent months.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.